although
infect
caus
agent
spread
rapidli
worldwid
drug
shown
suffici
effect
treat
previous
found
nafamostat
mesyl
exist
drug
use
dissemin
intravascular
coagul
dic
effect
block
merscov
proteininiti
cell
fusion
target
inhibit
merscov
infect
human
lung
epitheliumderiv
cell
establish
quantit
fusion
assay
depend
protein
found
nafamostat
mesyl
potent
inhibit
fusion
camostat
mesyl
less
activ
furthermor
nafamostat
mesyl
block
infect
cell
around
nm
averag
blood
concentr
intraven
administr
continu
infus
find
togeth
accumul
clinic
data
regard
safeti
make
nafamostat
like
candid
drug
treat
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
infect
sever
acut
respiratori
syndrom
coronaviru
caus
agent
coronaviru
pneumonia
diseas
spread
rapidli
worldwid
yet
drug
shown
suffici
effect
treat
therefor
drug
repurpos
offer
potenti
quickest
path
toward
diseas
treatment
genom
rna
coronavirus
surround
envelop
initi
viral
entri
requir
two
step
spike
protein
viral
envelop
bind
receptor
present
plasma
membran
protein
cleav
protein
cellular
proteas
sarscov
use
angiotensin
convert
enzym
merscov
use
receptor
cleav
cell
surfac
transmembran
proteas
serin
socal
prime
expos
fusion
peptid
protein
allow
attach
plasma
membran
result
fusion
envelop
plasma
membran
envelop
fusion
fusion
allow
viral
rna
enter
cytoplasm
replic
result
reduc
spread
sarscov
merscov
airway
accompani
reduc
sever
lung
patholog
mous
model
therefor
like
crucial
spread
diseas
develop
vivo
target
either
inhibit
prime
activ
suppress
express
like
effect
strategi
cure
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
previous
report
nafamostat
mesyl
exist
japanes
drug
use
acut
pancreat
dissemin
intravascular
coagul
dic
enhanc
fibrinolysi
effect
inhibit
merscov
proteininiti
membran
fusion
target
prime
activ
use
cell
fusion
assay
monitor
dual
split
protein
dsp
report
screen
fdaapprov
drug
librari
fig
cell
base
previou
work
togeth
other
establish
experiment
system
monitor
proteininiti
membran
fusion
test
depend
cell
express
fig
fusion
occur
target
cell
lack
either
fig
indic
cell
fusion
clearli
depend
previous
report
merscov
proteininiti
fusion
depend
supplementari
inform
fig
furthermor
cell
endogen
express
use
target
cell
fusion
scarc
occur
suggest
function
receptor
exist
type
lung
epitheli
cell
fig
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
test
activ
three
exist
japanes
drug
use
pancreat
andor
dic
nafamostat
mesyl
camostat
mesyl
gabex
mesyl
inhibitori
activ
serin
proteas
inhibit
proteininiti
fusion
fig
luciferas
activ
deriv
cell
carri
preform
report
complex
affect
drug
supplementari
inform
fig
indic
suppress
luciferas
activ
reflect
inhibit
fusion
drug
nafamostat
mesyl
show
greatest
activ
camostat
mesyl
less
activ
gabex
mesyl
inact
within
rang
concentr
test
next
use
lung
epitheliumderiv
cell
target
cell
endogen
express
might
better
reflect
physiolog
condit
kidney
cell
ectop
express
nafamostat
mesyl
inhibit
proteininiti
membran
fusion
rang
nm
camostat
mesyl
requir
nm
achiev
similar
extent
inhibit
fig
similar
inhibit
profil
observ
merscov
proteininiti
fusion
analyz
supplementari
inform
fig
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
therefor
nafamostat
mesyl
potent
camostat
mesyl
furthermor
drug
concentr
requir
fusion
inhibit
lung
epitheli
cell
lower
requir
inhibit
use
cell
fig
g
variou
comput
approach
recent
appli
find
exist
medic
target
consist
result
studi
rank
nafamostat
mesyl
significantli
higher
camostat
mesyl
note
sever
worldwid
commerci
avail
anticoagul
serin
proteas
inhibitor
target
factor
xa
thrombin
list
therefor
check
whether
anticoagul
affect
proteininiti
membran
fusion
contrari
expect
fail
inhibit
membran
fusion
fig
dsp
assay
identifi
nafamostat
mesyl
potent
inhibitor
siniti
membran
fusion
fig
g
inhibit
like
result
inhibit
plasma
membran
infect
cell
primarili
via
plasma
membran
pathway
infect
cell
via
endocytot
pathway
addit
plasma
membran
pathway
proceed
evalu
effect
nafamostat
mesyl
actual
infect
type
cell
without
pretreat
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
nafamostat
mesyl
base
appear
cytopath
effect
cpe
valu
cell
nm
pretreat
without
pretreat
cell
pretreat
without
pretreat
fig
cell
type
valu
much
smaller
cell
pretreat
nafamostat
mesyl
impli
nafamostat
mesyl
inhibit
entri
importantli
valu
cell
pretreat
around
nm
similar
previou
find
merscov
infect
howev
clearli
demonstr
nafamostat
mesyl
block
membran
fusion
step
viru
entri
activ
block
infect
cell
type
depend
find
crucial
develop
therapeut
strategi
report
recent
abnorm
coagul
elev
concentr
ddimer
characterist
dic
enhanc
fibrinolysi
may
influenc
prognosi
furthermor
murin
asthma
model
nafamostat
mesyl
attenu
respiratori
inflamm
block
activ
nfkb
critic
transcript
factor
inflammatori
cytokin
product
therefor
nafamostat
mesyl
expect
multipl
therapeut
effect
nafamostat
mesyl
prescrib
japan
mani
year
adequ
clinic
data
regard
safeti
accumul
suggest
evalu
patient
combin
antivir
drug
target
separ
process
need
viru
product
dsp
assay
monitor
membran
fusion
dsp
assay
use
cell
effector
cell
express
protein
target
cell
express
seed
cell
cultur
plate
x
one
day
assay
two
hour
dsp
assay
cell
treat
enduren
promega
madison
wi
usa
substrat
renilla
luciferas
activ
enduren
one
proteas
inhibitor
anticoagul
dissolv
dimethyl
sulfoxid
dmso
ad
plate
greiner
bioscienc
frickenhausen
germani
next
singl
cell
suspens
effector
target
cell
ad
well
use
multidrop
dispens
thermo
scientif
waltham
usa
incub
h
rl
activ
measur
use
centro
luminomet
berthold
germani
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
dsp
assay
use
cell
target
cell
seed
plate
x
one
day
assay
two
hour
dsp
assay
cell
treat
enduren
one
proteas
inhibitor
anticoagul
dissolv
dmso
ad
plate
cultur
medium
next
singl
cell
suspens
effector
cell
ad
well
use
multidrop
dispens
experi
done
quadrupl
effector
cell
cell
express
protein
target
cell
cell
express
cocultur
gfp
fluoresc
rl
luminesc
signal
gener
follow
reassoci
upon
cell
fusion
c
differ
combin
effector
target
cell
cocultur
result
rl
activ
measur
rel
cellfus
valu
calcul
normal
rl
activ
cocultur
cocultur
cell
express
protein
express
receptor
set
phase
contrast
imag
proteininitiatedcel
fusion
scale
bar
e
fusion
assay
use
wild
type
cell
f
three
clinic
use
pancreat
andor
anticoagul
drug
evalu
dsp
assay
effect
siniti
membran
fusion
rel
cellfus
valu
calcul
normal
rl
activ
cocultur
cocultur
dmso
alon
set
gabe
gabex
mesyl
nafa
nafamostat
mesyl
camo
camostat
mesyl
g
dsp
assay
use
left
right
cell
target
cell
constitut
express
cell
h
dsp
assay
use
cell
perform
presenc
variou
anticoagul
edo
edoxaban
riva
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
